Comparison of efficacy of steroidal and non-steroidal anti-inflammatory drugs after phacoemulsification: 3 month follow-up

Session Details

Session Title: PCO. Cataract Surgery Complications/Management

Session Date/Time: Tuesday 08/09/2015 | 08:00-10:30

Paper Time: 10:00

Venue: Room 1

First Author: : M.Kucharczyk POLAND

Co Author(s): :    P. Jurowski   W. Kubisiak   M. Chwia kowska-Karam   M. Wilczyski   S. Konarska   W. Omulecki     

Abstract Details

Purpose:

The aim of this study was to determine efficacy and safety of postoperative treatment with steroidal and non-steroidal anti-inflammatory drugs in patients after uneventful phacoemulsification.

Setting:

1.Department of Ophthalmology, Norbert Barlicki Memorial Teaching Hospital No. 1, University of Lodz, Poland. Head: Wojciech Omulecki MD, PhD 2.Department of Ophthalmology and Visual Rehabilitation, Central Veterans Hospital in Lodz. Medical University of Lodz, Poland Head: Piotr Jurowski

Methods:

58 eyes of 58 patients undergoing phacoemulsification cataract surgery, were evaluated in prospective study.Patients were randomized into 2 groups of postoperative treatment.All patients used the same antibiotic (fluoroquinolone ) 4 times a day for 10 days. Group I (34 eyes) used non-steroidal anti-inflammatory drug (bromfenak-Yellox ) 2 times a day for 30 days. Group II (24 eyes) used steroidal anti-infalammatory drug (loteprednol etabonate–Lotemax) 3 times a day for 30 days.Anterior and posterior chamber, best corrected visual acuity (BCVA), intraocular pressure, flare measurments, endothelial cell density and foveal thickness in 1,7,30 and 90 days after surgery were analyzed.

Results:

In Group I a statistically significant difference in BCVA was observed only in the 1st day after surgery, a significant improvement was not observed between the 1st and the 90th day of treatment. In group II a statistically significant improvement in BCVA was observed during the first 7 days of treatment. Afterwards, there was no significant difference in BCVA. The average macular thickness was not significantly different during the 3 months of treatment in both groups. In both groups laser flare-cell photometry value was equal in the 1st day of treatment. In group I there was a significant decrease in flare-cell photometry during the first 7 days.

Conclusions:

In both groups no postoperative complications were detected. Bromfenak and lotoprednol etabonate had similar efficacy and safety in the postoperative period after cataract uneventful phacoemulsification.

Financial Interest:

NONE